First-in-human Study of OVM-200 as a Therapeutic Cancer Vaccine

NCT05104515 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

36

Enrollment

INDUSTRY

Sponsor class

Conditions

Prostate Cancer
Non Small Cell Lung Cancer
Ovarian Cancer

Interventions

BIOLOGICAL: OVM-200

Sponsor

Oxford Vacmedix UK Ltd.